Accelerating DoD’s Fielding of Prototypes for Medical Countermeasures
More information coming soon!
Academic
Large/Nonprofit (2)
Small Business (2 year term)
The nomination window closes July 30.
MCDC 2212: Non-Clinical and Early Clinical Development of 3,4-Diaminopyridine Phosphate (3,4-DAPP) for Treatment of Botulinum Neurotoxin (BoNT) Intoxication
MCDC 2213: Development of Relevant Animal Models to Support Medical Countermeasure (MCM) Development against Traditional and Emerging Bio-Threats
MCDC 2214: Layered Medical Defense against Biological Threats
MCDC 2215: Small Molecules or Biologics as Host Targeted or Host Disease Process Targeted, Broad-Spectrum Medical Countermeasures (MCM) against Biological Threats of Concern
New Draft RPPs Released:
None at this time
New RFIs Released:
None at this time
FY22 Forecast
MCDC2212: Non-Clinical and Early Clinical Development of 3,4-Diaminopyridine Phosphate (3,4-DAPP) for Treatment of Botulinum Neurotoxin (BoNT) Intoxication
MCDC2213: Development of Relevant Animal Models to Support Medical Countermeasure (MCM) Development against Traditional and Emerging Bio-Threats
MCDC2214: Layered Medical Defense against Biological Threats
New Draft RPPs Released:
None at this time
New RFIs Released:
None at this time
MCDC2207: Needle-Free Vaccine Delivery Platform Prototypes
MCDC2206: Vaccine Encapsulation Prototype
MCDC2205: Adjuvant Activity to Vaccines Prototype
Non-Traditional Members
The Medical CBRN Defense Consortium (MCDC) was formed in response to the Government’s expressed interest to establish an Other Transaction Agreement (OTA) with an eligible entity or group of entities, to include industry, academic, and not-for-profit partners, for advanced development efforts to support the Department of Defense’s (DoD) medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel.
WHO CAN JOIN
Companies that are part of the US Industrial base, as well as new and emerging non-traditional defense contractors, are encouraged to join the MCDC and participate in Federally-funded R&D projects.
- Traditional Contractors
- Non-Traditionals (Companies that don’t typically participate in Federal R&D)
- Academia
- Non-Profit/ Not-For-Profit Research Institutions
Led by
MCDC research and prototype work is executed by project teams from a broad-based industry/ academia collaboration.
Sponsored by
Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense
Managed by
Collaboration Management Firm Advanced Technology International (ATI)